Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.56 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.56 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.56 |
| ▸ | FEN1 | P39748 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPEPPS | P55786 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407350 | 1.00 | ADORA3 (0.61) | ADORA3ADORA2AADORA2BADORA1ALDH1A1 | |
| SCHEMBL7651882 | 0.83 | ADORA3 (0.54) | ADORA3ADORA2AADORA2BADORA1ALDH1A1 | |
| SCHEMBL22716907 | 0.80 | HAVCR2 (0.48) | ALDH1A1CA12CA9HPGDSMN1; SMN2 | |
| SCHEMBL7656051 | 0.80 | ADORA3 (0.50) | ADORA3ADORA2AADORA2BADORA1ALDH1A1 | |
| SCHEMBL1268409 | 0.79 | DAO (0.55) | ADORA3ADORA2AADORA2BADORA1ALDH1A1 | |
| SCHEMBL6309992 | 0.78 | CA9 (0.62) | ALDH1A1CA12CA9CYP1A2KDM4E | |
| SCHEMBL31189202 | 0.78 | METAP2 (0.42) | CA12ERCC1FEN1CA9ERCC4 | |
| SCHEMBL22716853 | 0.78 | METAP2 (0.42) | CA12ERCC1FEN1CA9ERCC4 | |
| SCHEMBL31393212 | 0.78 | CA9 (0.62) | ALDH1A1CA12CA9CYP1A2KDM4E | |
| SCHEMBL31393153 | 0.78 | ALDH1A1 (0.49) | ALDH1A1CA12CA9KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570651-B2 | Quinazoline-2,4-dione derivatives as PARP inhibitors | Suzhou Four Health Pharmaceuticals Co., Ltd. (CN) | 2026-03-10 | — | — | US | disclosed |
| US-12440484-B2 | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2025-10-14 | — | — | US | disclosed |
| EP-3969450-B1 | QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORS | SUZHOU FOUR HEALTH PHARMACEUTICALS CO LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-3969450-B1 | QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORS | SUZHOU FOUR HEALTH PHARMACEUTICALS CO LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| US-20230079386-A1 | 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2023-03-16 | — | — | US | disclosed |
| US-20220227757-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORS | SHUZHOU FOUR HEALTH PHARMACEUTICALS CO., LTD. (CN) | 2022-07-21 | — | — | US | disclosed |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3976602-A1 | 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2022-04-06 | — | — | EP | disclosed |
| CN-114206864-A | Quinazoline-2, 4-dione derivatives as PARP inhibitors | 苏州四体康宸医药科技有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-113874369-A | 1,3, 4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2021-12-31 | — | — | CN | disclosed |
| US-9957283-B1 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-05-01 | — | — | US | disclosed |
| US-9957283-B1 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-05-01 | — | — | US | disclosed |
| US-9090568-B2 | Quinazolinediones and their use | IMPACT THERAPEUTICS, INC. (CN) | 2015-07-28 | — | — | US | disclosed |
| US-9090568-B2 | Quinazolinediones and their use | IMPACT THERAPEUTICS, INC. (CN) | 2015-07-28 | — | — | US | disclosed |
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| US-20140031358-A1 | QUINAZOLINEDIONES AND THEIR USE | Eternity Bioscience Inc. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031358-A1 | QUINAZOLINEDIONES AND THEIR USE | Eternity Bioscience Inc. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2012125521-A1 | QUINAZOLINEDIONES AND THEIR USE | Eternity Bioscience Inc. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-6407116-B1 | 2,4-DIOXO-1,2,3,4-TETRAHYDROQUINAZOLINE DERIVATIVES; ANTIALLERGENS, ANTIASTHMATICS, ANTIHISTAMINES, AND ANTIINFLAMMATORY AGENTS | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1026160-A1 | NITROGENOUS FUSED-RING COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME, AND DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079386-A1 | 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC11, HDAC3 | ADORA3 3568/4885ADORA2A 4551/4885ADORA2B 4256/4885 |
| US-12440484-B2 | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | HDAC1, HDAC11, HDAC3 | ADORA3 3568/4885ADORA2A 4551/4885ADORA2B 4256/4885 |
| US-20140031358-A1 | QUINAZOLINEDIONES AND THEIR USE | PARP1, PARP15, PARP11 | ADORA3 618/4885ADORA2A 666/4885ADORA2B 969/4885 |
| US-12570651-B2 | Quinazoline-2,4-dione derivatives as PARP inhibitors | PARP1, PARP3, PARP2 | ADORA3 890/4885ADORA2A 1905/4885ADORA2B 2303/4885 |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | ADORA3 1098/4885ADORA2A 1178/4885ADORA2B 849/4885 |
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP12, MMP10 | ADORA3 2138/4885ADORA2A 2559/4885ADORA2B 1267/4885 |
| US-20220227757-A1 | QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP11 | ADORA3 2119/4885ADORA2A 1521/4885ADORA2B 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.